clinical trial · NCT06561542
A Phase I Study of LX22001 for Injection in Healthy Subjects
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.·phase1·recruiting·n = 70
HealthyLX22001 for InjecitonTegoprazan tabletEsomeprazole sodium for injection
brief summary
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
started
Aug 5, 2024
primary completion
Nov 21, 2025
completion
Nov 21, 2025
last updated
Aug 20, 2024
official title
A Phase I, Escalating Single and Multiple Dose Study of LX22001 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Bioavailability in Healthy Subjects.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol